RxDoctor Payments Data

Ross Anderson

Urology · Reno, NVNPI 1407275209

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,894 of the $6,679 with a category attached, or 73.3%. 16 manufacturers reported payments, led by Boston Scientific at 52.1% of the total. Reporting peaked in 2019 at $1,515 and has fallen 63.1% since, to $559 in 2025.

$6,679in general payments, 2019–2025

Across 175 payments — averaging $38.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Intuitive Surgical$2K
  • Coloplast$496
  • AbbVie$240
  • Laborie Medical Technologies Corp.$215
  • Astellas Pharma US Inc$148
  • plus $583 from 10 others

What the payments were for

  • Travel & lodging$1,54023%
  • Food & beverage$4,89473%
  • Education$2454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,679 in reported general payments places this provider in the 55th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$217,810
Medicare patients
494
Services billed
2,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron22$19,454
Tamsulosin Hcl156$2,926
Oxybutynin Chloride ErOxybutynin Chloride53$1,211
Potassium Citrate ErPotassium Citrate19$1,182
Finasteride78$1,053
Alfuzosin Hcl ErAlfuzosin Hcl11$376
Trospium Chloride11$300
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim49$168
Cephalexin17$124
Oxycodone Hcl30$83
Amoxicillin17$53
Ciprofloxacin Hcl12$40
Meloxicam13$9

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$148$19,45422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 63 urology providers in Nevada.

Other urology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →